Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (3755)	5/11/2001 10:05:19 AM
From: scaram(o)uche	Respond to of 52153

No, I said that I didn't own it. Nope, just very pleased to see a second "tool" company go out at a big premium, when they're the "out of favor" subsector. I do own a very, very, very, very small piece of a private company that is a RSTA competitor. That chunk just went up in value, so perhaps it's now " very, very, very" instead of " very, very, very, very". In any event, wouldn't even put a noticeable ripple in the college fund.

To: Harold Engstrom who wrote (3755)	5/11/2001 10:13:24 AM
From: Biomaven	Respond to of 52153

This graph of NCE approval times is interesting: fda.gov I hadn't realized just how many drug approvals take more than 12 months. I don't fully understand the graph, though - if it really was a graph of NDA's received and approved in 36 months shouldn't all the graphs end at 100% because the graph goes out to 36 months? I would assume the missing numbers are NDA's that were approved in longer than 36 months rather than NDA's that were rejected (I think the latter would have been a bigger number). This table of Subpart H approvals (surrogate endpoint) is also interesting: fda.gov Peter BTW, I commented briefly on the RSTA deal over on the munch thread: Message 15786731